Oleg Zherebtsov, CEO of Solopharm, ranked 2nd in “Influence Rating for 2024: Entrepreneurs, Heads of Commercial Structures” (PharmVestnik, Feb. 2025)
No. 1 in ophthalmologist recommendations for the company's products (Ipsos Prindex, Q1 2024)
No. 1 in recommendations of the company's products among ENT doctors (Ipsos Prindex, Q1 2024)
No. 5 for company product recommendations among pediatricians (Ipsos Prindex, Q1 2024)
Solopharm #1 among all manufacturers in Ophthalmology in 2024 (based on data from IQVIA Retail Audit, IQVIA Contracts 44FZ, Headway Ophthalmic Surgery, by volume)
Solopharm in the Top 5 manufacturers by sales growth rate in volume terms in the retail ECOM segment in 2024 (DSM estimates, Feb. 2025)
Solopharm unveiled a new milestone – the Matrix Wall, its proprietary cleanroom design and manufacturing facility
Solopharm in Top 5 manufacturers by number of physician prescriptions (IPSOS, Jan. 2025, PrIndex)
Solopharm ranked in the Top 15 manufacturers with the highest share of launches in prescription portfolios in 2024 (Ipsos, Feb. 2025)
Solopharm ranked 9th in “Influence Rating for 2024: Local Manufacturing Companies” (PharmVestnik, Feb. 2025)
Solopharm in 4th place in the ranking of state segment manufacturers in 2024 (DSM, in volume terms, Feb. 2025)
Solopharm ranked No. 1 by volume of ampoule solution sales in the retail market in 2024 (DSM, pharmacy sales, Feb. 2025)
Solopharm in the Top 10 manufacturers in digital promotion in 2024 (Ipsos, Feb. 2025)
Solopharm in the Top 20 drug manufacturers by pharmacy sales value in 2024 (DSM, Mar. 2025; based on IQVIA data, Feb. 2025)
Solopharm in Top 10 drug manufacturers by volume of sales in 2024 (DSM, whole pharmaceutical market, Mar. 2025)
Solopharm in the Top 3 manufacturers of INN Sodium Chloride in government procurement at the end of 2024 (DSM, pharmacy sales, Mar. 2025)
Solopharm ranked 6th among companies with the highest number of OTC launches in 2024 (DSM, Mar. 2025)
Solopharm in Top 20 drug manufacturers by value of pharmacy sales in 2m 2025 (based on CRPT data, Apr. 2025)
Fridifin in the Top 10 successful product launches in Q4 2024 (IPSOS, Feb. 2025)
Trecrezan in the Top 15 OTC brands in pharmacy sales in 2024 (DSM, Mar. 2025)
Angidak recognized as one of the successful brands with high growth in “Knowledge” and “Consumption” indicators (IPSOS, Mar. 2025)